How to address the issue of access to new drugs in multiple myeloma

Paul Richardson, MD of the Dana-Farber Cancer Institute, Boston, MA discusses the access to new multiple myeloma (MM) drugs with Vivien de Gunzburg, Founder of the de Gunzburg Myeloma Research Foundation (DGMRF). This video is part of a series of videos on Vivien de Gunzburg’s patient story and work in the field of MM; he was diagnosed with MM 13 years ago and Dr Richardson has been part of his care team. Vivien de Gunzburg points out the importance of collaboration between international foundations and groups, pharma companies and governments in order to address the issue of drug cost. Dr Richardson also explains that it is important to consider the impact of a drug on society when considering costs and Vivien de Gunzburg stresses the importance of finding a cure.
Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.

DGMRF: http://www.gunzburg-myeloma.org/
Paul Richardson’s profile: http://www.dfhcc.harvard.edu/insider/member-detail/member/paul-g-richardson-md/

Share this video